Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02071329

Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge

A Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (Vaccine FP-01.1) in Healthy Volunteers Following Virus Challenge

Sponsor: Immune Targeting Systems Ltd

Conditions Influenza A

Interventions Placebo Vaccine FP-01.1 Virus Challenge

Updated 5 times since 2017 Last updated: Oct 4, 2016 Started: Jan 31, 2014 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Influenza A and is currently completed. Immune Targeting Systems Ltd leads this study, which shows 5 recorded versions since 2014 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Immune Targeting Systems Ltd

Data source: Immune Targeting Systems Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom